Taysha Gene Therapies, Inc.
TSHAHeld by 8 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying8 funds opened new positions. Next phase2 readout (TSHA-101): Mar 2027. Short interest: 17.1% of float.
Held by 8 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying8 funds opened new positions. Next phase2 readout (TSHA-101): Mar 2027. Short interest: 17.1% of float.
Taysha Gene Therapies, Inc. is a biotech firm specializing in the creation and market introduction of gene therapies that utilize adeno-associated virus (AAV) vectors. Its core mission is to tackle inherited diseases affecting the central nervous system (CNS). The company's development pipeline features several key programs: TSHA-120 is aimed at giant axonal neuropathy; TSHA-102 is in development for Rett syndrome; TSHA-121 and TSHA-118 are both being advanced for CLN1 disease; TSHA-105 addresses SLC13A5 Deficiency; and TSHA-101 targets GM2 gangliosidosis. Furthermore, Taysha has forged a strategic alliance with The University of Texas Southwestern Medical Center to jointly advance and bring to market innovative gene therapy solutions. Founded in 2019, the company operates from its headquarters in Dallas, Texas.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.